Epicardial adipose tissue is associated with the development of atrial fibrillation and heart failure with preserved ejection fraction, and targeted therapies such as weight loss, antidiabetic agents, and statins can reduce EAT volume.
Do therapies targeting epicardial adipose tissue reduction improve cardiovascular outcomes such as atrial fibrillation and heart failure with preserved ejection fraction?
Epicardial adipose tissue is a metabolically active fat depot linked to the development of AFIB and HFpEF, and therapies targeting its reduction may improve cardiovascular outcomes.
Epicardial adipose tissue (EAT) has been associated with the development of many cardiovascular abnormalities, of which the development of atrial fibrillation (AFIB) in this group of patients is not an uncommon finding. Several mechanisms have been proposed to explain the role of EAT in the development of AFIB. It involves cardiac remodeling owing to the underlying fatty infiltration and the subsequent inflammation and fibrosis. This leads to the formation of ectopic foci that can lead to AFIB. Some studies propose that structural and valvular heart disease and increased hemodynamic stress further augment the development of AFIB in patients with underlying EAT. The degree of development of AFIB is also related to EAT thickness and volume. Therefore, EAT quantification can be used as an imaging technique to predict cardiovascular outcomes in these patients. Obesity also plays an important role in the development of AFIB both as an independent factor and by leading to adipose tissue deposition on the epicardial tissue. Understanding the pathophysiology of EAT is important as it can lead to the development of therapies that can target obesity as a risk factor for preventing AFIB. Some promising therapies have already been investigated for decreasing the risk of AFIB in patients with EAT. Dietary changes and weight loss have been shown to reduce the deposition of fat on epicardial tissue. Antidiabetic drugs and statin therapy have also shown promising results. Bariatric surgery has been shown to decrease EAT volume on echocardiography in obese patients.
Zain et al. (Thu,) conducted a review in Atrial Fibrillation (AFIB) and Heart Failure With Preserved Ejection Fraction (HFpEF). EAT-targeted therapies (weight loss, antidiabetic agents, statins) was evaluated. Epicardial adipose tissue is associated with the development of atrial fibrillation and heart failure with preserved ejection fraction, and targeted therapies such as weight loss, antidiabetic agents, and statins can reduce EAT volume.